Literature DB >> 26147536

Successful treatment of refractory pure red cell aplasia with bortezomib after allogeneic haematopoietic cell transplantation in a patient with alpha-beta subcutaneous panniculitis-like T cell lymphoma.

J L Shahan1, G C Hildebrandt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26147536     DOI： 10.1111/tme.12216

Source DB:  PubMed          Journal:  Transfus Med        ISSN： 0958-7578            Impact factor:   2.019


× No keyword cloud information.
  4 in total

Review 1.  Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Authors:  Javier Marco-Ayala; Inés Gómez-Seguí; Guillermo Sanz; Pilar Solves
Journal:  Bone Marrow Transplant       Date:  2020-11-14       Impact factor: 5.483

2.  Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation.

Authors:  Yang Gao; Fei Gao; Jimin Shi; Huarui Fu; He Huang; Yanmin Zhao
Journal:  J Zhejiang Univ Sci B       Date:  2021-08-15       Impact factor: 3.066

3.  Effective treatment of refractory acquired pure red blood cell aplasia with eltrombopag and sirolimus: a case report.

Authors:  Yuzhou Huang; Xianyong Jiang; Bing Han
Journal:  Ther Adv Hematol       Date:  2020-07-20

4.  Antigen-Specific Immunoadsorption With the Glycosorb® ABO Immunoadsorption System as a Novel Treatment Modality in Pure Red Cell Aplasia Following Major and Bidirectional ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Ammon Handisurya; Nina Worel; Werner Rabitsch; Marija Bojic; Sahra Pajenda; Roman Reindl-Schwaighofer; Wolfgang Winnicki; Andreas Vychytil; Hanna A Knaus; Rainer Oberbauer; Kurt Derfler; Philipp Wohlfarth
Journal:  Front Med (Lausanne)       Date:  2020-10-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.